Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Expanded_access × larotrectinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Observational 3 Interventional 3 Expanded_access 1

Sponsor

Conditions

Tumors Harboring NTRK Fusion 1

Interventions

nilotinib 4 dabrafenib 4 Nivolumab 4 Afatinib 4 trametinib 3 midostaurin 3 elotuzumab 3 3-Iodobenzylguanidine 3 venetoclax 2 tucatinib 2 tempol 2 talimogene laherparepvec 2 ruxolitinib 2 regorafenib 2 pomalidomide 2 olaparib 2 niraparib 2 lenvatinib 2 ibrutinib 2 gilteritinib 2 ceritinib 2 brexucabtagene autoleucel 2 balstilimab 2 axicabtagene ciloleucel 2 avapritinib 2 atezolizumab 2 abemaciclib 2 Trastuzumab 2 Suspensions 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Approved for marketing

Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡